<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id><journal-title>BMC Medical Genetics</journal-title><issn pub-type="epub">1471-2350</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2350-8-44</article-id><article-id pub-id-type="pmid">17617923</article-id><article-id pub-id-type="doi">10.1186/1471-2350-8-44</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Secretory granule neuroendocrine protein 1 (<italic>SGNE1</italic>) genetic variation and glucose intolerance in severe childhood and adult obesity</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Bouatia-Naji</surname><given-names>Nabila</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>nabila.bouatia-naji@good.ibl.fr</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Vatin</surname><given-names>Vincent</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>vincent.vatin@good.ibl.fr</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Lecoeur</surname><given-names>C&#x000e9;cile</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>cecile@good.ibl.fr</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Heude</surname><given-names>Barbara</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>heude@vjf.inserm.fr</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Proen&#x000e7;a</surname><given-names>Christine</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>christine@good.ibl.fr</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Veslot</surname><given-names>Jacques</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jacques.veslot@gmail.com</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Jouret</surname><given-names>B&#x000e9;atrice</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>jouret.b@chu-toulouse.fr</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Tichet</surname><given-names>Jean</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>jean.tichet@irsa.asso.fr</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Charpentier</surname><given-names>Guillaume</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>kerbonac@free.fr</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Marre</surname><given-names>Michel</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>michel.marre@bch.ap-hop-paris.fr</email></contrib><contrib id="A11" contrib-type="author"><name><surname>Balkau</surname><given-names>Beverley</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>balkau@vjf.inserm.fr</email></contrib><contrib id="A12" corresp="yes" contrib-type="author"><name><surname>Froguel</surname><given-names>Philippe</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I7">7</xref><email>pfroguel@imperial.ac.uk</email></contrib><contrib id="A13" contrib-type="author"><name><surname>Meyre</surname><given-names>David</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>meyre@good.ibl.fr</email></contrib></contrib-group><aff id="I1"><label>1</label>CNRS-8090-Institute of Biology, <italic>Pasteur </italic>Institute, Lille, France</aff><aff id="I2"><label>2</label>INSERM 780-IFR69, Univ <italic>Paris Sud</italic>, Villejuif, France</aff><aff id="I3"><label>3</label>INSERM U563, Children's Hospital, Toulouse, France</aff><aff id="I4"><label>4</label>IRSA, La Riche, France</aff><aff id="I5"><label>5</label>Endocrinology-Diabetology Unit, <italic>Corbeil-Essonne </italic>Hospital, France</aff><aff id="I6"><label>6</label>INSERM U695, <italic>Bichat </italic>Hospital, Paris, France</aff><aff id="I7"><label>7</label>Genomic Medicine, Hammersmith Hospital, Imperial College London, UK</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>7</day><month>7</month><year>2007</year></pub-date><volume>8</volume><fpage>44</fpage><lpage>44</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/8/44"/><history><date date-type="received"><day>22</day><month>3</month><year>2007</year></date><date date-type="accepted"><day>7</day><month>7</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 Bouatia-Naji et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Bouatia-Naji et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Bouatia-Naji Nabila nabila.bouatia-naji@good.ibl.fr </dc:author><dc:title> Secretory granule neuroendocrine protein 1 (SGNE1) genetic variation and glucose intolerance in severe childhood and adult obesity </dc:title><dc:date>2007</dc:date><dcterms:bibliographicCitation>BMC Medical Genetics 8(1): 44-. (2007)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2350(2007)8:1&#x0003c;44&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2350</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>7B2 is a regulator/activator of the prohormone convertase 2 which is involved in the processing of numerous neuropeptides, including insulin, glucagon and pro-opiomelanocortin. We have previously described a suggestive genetic linkage peak with childhood obesity on chr15q12-q14, where the 7B2 encoding gene, <italic>SGNE1 </italic>is located. The aim of this study is to analyze associations of <italic>SGNE1 </italic>genetic variation with obesity and metabolism related quantitative traits.</p></sec><sec sec-type="methods"><title>Methods</title><p>We screened <italic>SGNE1 </italic>for genetic variants in obese children and genotyped 12 frequent single nucleotide polymorphisms (SNPs). Case control analyses were performed in 1,229 obese (534 children and 695 adults), 1,535 individuals with type 2 diabetes and 1,363 controls, all French Caucasians. We also studied 4,922 participants from the D.E.S.I.R prospective population-based cohort.</p></sec><sec><title>Results</title><p>We did not find any association between <italic>SGNE1 </italic>SNPs and childhood or adult obesity. However, the 5' region SNP -1,701A&#x0003e;G associated with higher area under glucose curve after oral glucose tolerance test (p = 0.0005), higher HOMA-IR (p = 0.005) and lower insulinogenic index (p = 0.0003) in obese children. Similar trends were found in obese adults. SNP -1,701A&#x0003e;G did not associate with risk of T2D but tends to associate with incidence of type 2 diabetes (HR = 0.75 95%CI [0.55&#x02013;1.01]; p = 0.06) in the prospective cohort.</p></sec><sec><title>Conclusion</title><p><italic>SGNE1 </italic>genetic variation does not contribute to obesity and common forms of T2D but may worsen glucose intolerance and insulin resistance, especially in the background of severe and early onset obesity. Further molecular studies are required to understand the molecular bases involved in this process.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Obesity is a major risk factor for metabolic disorders such as hypertension, dyslipidemia and type 2 diabetes (T2D) [<xref ref-type="bibr" rid="B1">1</xref>]. The increased prevalence of metabolic diseases is now affecting young populations as a direct consequence of the increase in childhood obesity [<xref ref-type="bibr" rid="B2">2</xref>]. There is evidence for a genetic contribution to the obesity epidemic, especially, for severe forms of obesity, including childhood obesity and severe adult obesity (BMI &#x02265; 40 Kg/m<sup>2</sup>) [<xref ref-type="bibr" rid="B3">3</xref>].</p><p>We previously performed a family based genome-wide scan using microsatellite markers and identified a suggestive obesity susceptibility linkage peak on chromosome 15q12-14 [<xref ref-type="bibr" rid="B4">4</xref>]. <italic>SGNE1 </italic>(Secretory Granule NeuroEndocrine protein 1) coding for 7B2 peptide is located within the 95% confidence interval of this linkage peak [<xref ref-type="bibr" rid="B4">4</xref>]. 7B2 mRNA and protein are located in either primarily neuronal (e.g hypothalamus) or endocrine (e.g pancreas and gastrointestinal tract) tissues [<xref ref-type="bibr" rid="B5">5</xref>]. 7B2 is a chaperone of the proprotein convertase (PC) 2 [<xref ref-type="bibr" rid="B6">6</xref>]. Pro7B2, the 7B2 peptide precursor, regulates the processing of proPC2 and is essential for the activation and regulation of PC2 in secretory granules of neuroendocrine cells [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>PC2 is an endoprotease involved in the processing of several neuropeptides including proinsulin [<xref ref-type="bibr" rid="B8">8</xref>], proglucagon [<xref ref-type="bibr" rid="B9">9</xref>], pro-opiomelanocortin (POMC) [<xref ref-type="bibr" rid="B10">10</xref>] and the cocaine amphetamine regulated transcript (CART) [<xref ref-type="bibr" rid="B11">11</xref>]. 7B2 may also affect regulated hormone secretion [<xref ref-type="bibr" rid="B12">12</xref>]. Mice studies have shown that invalidation of the genes encoding either PC2 or 7B2 generates major hormone processing deficiency <italic>in vivo </italic>[<xref ref-type="bibr" rid="B13">13</xref>] and is lethal for gene encoding 7B2 in some genetic backgrounds in mice [<xref ref-type="bibr" rid="B14">14</xref>]. Interestingly, adrenalectomization of 7B2 knockout mice avoided the lethal phenotype but these animals developed severe obesity [<xref ref-type="bibr" rid="B15">15</xref>].</p><p>According to this physiological data and the genetic position of <italic>SGNE1 </italic>under an obesity linkage peak, we hypothesized that <italic>SGNE1 </italic>is a positional candidate gene for obesity and metabolic disorders in French Caucasians.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Subjects</title><sec><title>Obese</title><p>We genotyped 630 obese children (defined as BMI &#x0003e; 97<sup>th </sup>percentile for age and sex according to a French cohort [<xref ref-type="bibr" rid="B16">16</xref>]) selected from 424 nuclear families recruited in Lille through a national media campaign. Genotypes from 105 unrelated obese children recruited in the Children's hospital in Toulouse were also included and, in total, 735 obese children were studied. We selected 534 unrelated obese children for case/control studies. We also genotyped 1219 obese adults (BMI &#x02265; 30) recruited in Lille or at H&#x000f4;tel-Dieu hospital in Paris. We selected 695 unrelated severely obese (BMI &#x02265; 40) and 620 unrelated moderately obese (30 &#x02264; BMI &#x0003c; 40) adults for case/control analyses. The moderate obese adults are sib pairs of severely obese and parents of obese children.</p></sec><sec><title>Type 2 diabetics</title><p>We genotyped 360 unrelated type 2 diabetic patients recruited by the <italic>Centre National de la Recherche Scientifique </italic>(CNRS) and <italic>Institut Pasteur </italic>in Lille and 1175 unrelated type 2 diabetic patients recruited from Endocrinology-Diabetology Department in the Corbeil-Essonne Hospital, Evry.</p></sec><sec><title>Controls</title><p>Control participants were composed of 623 individuals recruited by CNRS and Institut Pasteur in Lille or through the "<italic>Fleurbaix-Laventie Ville Sant&#x000e9;</italic>" study. Additional 740 control subjects were selected among participants of the Data from the Epidemiology Study on the Insulin Resistance (D.E.S.I.R) study. Control participants were pooled for case control analyses. &#x003c7;<sup>2 </sup>tests did not show significant difference in genotype and allele frequencies between both control groups (0.253 &#x02264; p &#x02264; 0.886).</p></sec><sec><title>Cohort</title><p>Participants are from the D.E.S.I.R study, a 9 year follow-up study. We genotyped 4,922 subjects that had data available at baseline (M/F ratio: 49.6/50.4%; age = 47.2 &#x000b1; 10.0 yrs; BMI = 24.7 &#x000b1; 3.8 kg/m<sup>2</sup>). Among them, 4,387 subjects were normoglycemic (fasting plasma glucose&#x0003c;6.1 mmol/l) and 3,370 (77%) were followed for incident impaired fasting glucose (IFG) and T2D. A total of 3,645 participants were non obese (BMI&#x0003c;27 kgm<sup>2</sup>) at baseline, and 2,829 (78%) could be followed for overweight and obesity. After 9 years of follow-up, 2,053 subjects were both non obese and normoglycemic. T2D was defined as fasting plasma glucose &#x02265; 7.0 mmol/l and/or diabetes treatment.</p><p>All adult participants and parents of children signed informed consent. The genetic study was approved by ethical committees at corresponding recruitment centres in <italic>H&#x000f4;tel-Dieu </italic>in Paris, C.H.R.U in Lille, <italic>Bic&#x000ea;tre </italic>Hospital for D.E.S.I.R study, Toulouse Children's Hospital.</p></sec></sec><sec><title>Measurements</title><p>Weight and height were measured by trained personnel and BMI was calculated as weight/height<sup>2 </sup>(Kg/m<sup>2</sup>). During an oral glucose tolerance test (OGTT), participants received after a 12 h overnight fast 1 g glucose/kg if subject's weight was &#x0003c;50 kg or 75 g glucose if subject's weight was &#x02265; 50 kg. Blood samples were collected after 0, 30, 60, 90 and 120 min for measurement of plasma glucose using the glucose oxidase procedure and insulin using double-antibody radioimmunoassays. Glucose and insulin related traits were only analyzed in subgroups of 590 obese children and 575 obese adults, all normal glucose tolerant (NGT) (fasting glycemia&#x0003c;6.1 mmol/l). The insulinogenic index was calculated as (Ins<sub>30min</sub>-Ins<sub>0min</sub>/Glc<sub>30min</sub>-Glc<sub>0min</sub>) and HOMA-IR was calculated as Ins<sub>0min</sub>/[22.5e<sup>-ln(Glc0min)</sup>].</p></sec><sec><title>Screening for SNPs</title><p><italic>SGNE1 </italic>has 6 exons and spans 55 kb. We directly sequenced coding regions including exons, exons/introns boundaries, 3 kb upstream ATG codon (including non coding exon1 and intron1) and 1 Kb downstream the stop codon. We used DNA from 48 unrelated obese children and 24 unrelated control adults. PCR amplifications were purified with Montage PCR384 Multiscreen<sup>&#x000ae;</sup>S384PCR (Millipore). Sequencing was performed using the automated ABI Prism 3730xl DNA sequencer in combination with the Big Dye Terminator cycle (Applied Biosystems) and purification sequencing reaction with MultiScreen<sup>&#x000ae;</sup>SEQ384 filter plates (Millipore). Data from HapMap phase I was used to select TagSNPs (MAF&#x02265;0.05 in CEU population) to improve the genetic coverage of <italic>SGNE1</italic>.</p></sec><sec><title>Genotyping</title><p>SNPs identified by direct sequencing were genotyped using either the LightCycler&#x02122; or LightTyper&#x02122; technologies (Roche). TagSNPs selected from HAPMAP I, and SNP -1,071A&#x0003e;G in the cohort were genotyped by the Applied Biosystems SNPlex&#x02122; technology based on the Oligonucleotide Ligation Assay (OLA) combined with multiplex PCR target amplification. Allelic discrimination was performed through capillary electrophoresis analysis using an Applied Biosystems 3730xl DNA Analyzer and GeneMapper3.7 software. All SNPs were re-genotyped in a subset of 379 individuals by direct sequencing to check for genotyping discrepancies. Genotyping error rates were &#x02264; 0.01 for all SNPs. Hardy-Weinberg equilibrium (HWE) was tested in controls and was verified for all SNPs (0.11 &#x02264; p &#x02264; 0.68).</p></sec><sec><title>Statistical analyses</title><p>Tests for deviation from HWE and for association were performed by the De Finetti program [<xref ref-type="bibr" rid="B17">17</xref>]. Case control analyses for haplotype were performed using THESIAS software [<xref ref-type="bibr" rid="B18">18</xref>]. All possible combinations of 1 to 4 SNPs were tested. Haplotypes with a frequency of less than 1% were excluded. Analyses were conducted on inferred and observed genotypes. OGTT glycaemia and insulinemia were analysed by General Linear Model ANOVA for repeated measures. All other quantitative traits (QTs) were analyzed by a univariate ANOVA General Linear Model adjusted for sex, age, BMI, using SPSS 14.0 for windows. Haplotypes associations with QTs were performed using UNPHASED software [<xref ref-type="bibr" rid="B19">19</xref>]. Bonferroni correction was applied to quantitative traits as significance threshold (0.05) divided by the number of tests (12 SNPs &#x000d7; 9 QTs = 108) per population. Threshold of significance after adjustment for multiple testing was 0.0005. Survival curves were modelled and analysed by the Kaplan-Meier and Cox tests using R Foundation statistical software (version 2.4.0)</p></sec></sec><sec><title>Results</title><p>We identified four frequent (minor allele frequency &#x02265; 5%) and eight rare SNPs by direct sequencing. Frequent SNPs (-1,839A&#x0003e;T, -1,701A&#x0003e;G, -706C&#x0003e;G -304A&#x0003e;G) were all located in the 5' region. In order to improve the genetic coverage of <italic>SGNE1</italic>, we selected TagSNPs from the HapMap phase I. SNPs with a low genotype call rate (&#x0003c;70%) were not analyzed. Thus, eight TagSNPs all located in introns were added and 12 SNPs (Figure <xref ref-type="fig" rid="F1">1</xref>) were investigated for association with obesity and related phenotypes.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold><italic>SGNE1 </italic>genetic variation (A) and LD (B) maps. Genetic variation map</bold>: SNPs with MAF &#x02265; 0.05 are indicated in bold character. SNPs positions were allocated according to the human genome variation society nomenclature <ext-link ext-link-type="uri" xlink:href="http://www.hgvs.org/mutnomen/disc.html#SNP"/>. IVS = intronic variation sequence. rs numbers were indicated for frequent SNPs when available. SNP 1,701A&#x0003e;G is underlined. <bold>LD map</bold>: LD map was generated using Haploview program. SNPs positions are on scale. LD (measured by correlation coefficient R<sup>2</sup>) was presented in boxes that correspond to the intersection of two SNPs (e.g. LD between rs13850_1839 and rs11635997_1071 is of 6%).</p></caption><graphic xlink:href="1471-2350-8-44-1"/></fig><p>Clinical characteristics of the populations studied are presented in Table <xref ref-type="table" rid="T1">1</xref>. Obesity case control analyses are presented in the Table <xref ref-type="table" rid="T2">2</xref>. None of the <italic>SGNE1 </italic>SNPs or haplotype combination (data not shown) studied showed a significant association with severe forms of obesity in our populations. Thus, as expected, the contribution of these SNPs to linkage with childhood obesity observed on chromosome 15q12-q14 was not significant (data not shown). We also analyzed association of <italic>SGNE1 </italic>SNPs with moderate obesity (30 &#x02264; BMI &#x02264; 40). Case control analyses in additional 620 subjects did not show significant association with this less severe form of obesity (0.06 &#x02264; p &#x02264; 0.87; data not shown).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinical characteristics of the populations studied.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><bold>Obese Children</bold><break/><bold>N = 735</bold></td><td align="center"><bold>Obese Adults</bold><break/><bold>N = 1315</bold></td><td align="center"><bold>T2D</bold><break/><bold>N = 1535</bold></td><td align="center"><bold>Control 1</bold><break/><bold>N = 623</bold></td><td align="center"><bold>Control 2</bold><break/><bold>N = 740</bold></td></tr></thead><tbody><tr><td align="left"><bold>Age (years)</bold></td><td align="center">11.3 &#x000b1; 3.2</td><td align="center">48 &#x000b1; 13</td><td align="center">59 &#x000b1; 11</td><td align="center">50.9 &#x000b1; 12</td><td align="center">53 &#x000b1; 5.6</td></tr><tr><td align="left"><bold>BMI (kg/m</bold><sup>2</sup><bold>)</bold></td><td align="center">28.8 &#x000b1; 6.2</td><td align="center">41.5 &#x000b1; 8.8</td><td align="center">29.3 &#x000b1; 5.8</td><td align="center">22.9 &#x000b1; 2.3</td><td align="center">23 &#x000b1; 1.8</td></tr><tr><td align="left"><bold>Sex ratio (F/M)</bold></td><td align="center">386/349</td><td align="center">874/441</td><td align="center">890/645</td><td align="center">380/243</td><td align="center">444/296</td></tr><tr><td align="left"><bold>Obesity (%)</bold></td><td align="center">100</td><td align="center">100</td><td align="center">37</td><td align="center">0</td><td align="center">0</td></tr><tr><td align="left"><bold>Type 2 Diabetes (%)</bold></td><td align="center">1</td><td align="center">29</td><td align="center">100</td><td align="center">0</td><td align="center">0</td></tr><tr><td align="left"><bold>NGT (%)</bold></td><td align="center">94</td><td align="center">52</td><td align="center">0</td><td align="center">100</td><td align="center">100</td></tr><tr><td align="left"><bold>Fasting Glucose (mmol/l)</bold></td><td align="center">4.95 &#x000b1; 0.5</td><td align="center">6.66 &#x000b1; 2.6</td><td align="center">9.40 &#x000b1; 3.3</td><td align="center">5.00 &#x000b1; 0.4</td><td align="center">5.05 &#x000b1; 0.88</td></tr><tr><td align="left"><bold>Fasting Insulin (pmol/l)</bold></td><td align="center">81.0 &#x000b1; 58</td><td align="center">88.2 &#x000b1; 60</td><td align="center">66.0 &#x000b1; 54</td><td align="center">33.5 &#x000b1; 25</td><td align="center">30.5 &#x000b1; 22</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Obesity and T2D case control analyses for <italic>SGNE1 </italic>SNPs. OR: odds ratio. ORs and p values are for allele frequencies comparisons. &#x003c7;<sup>2 </sup>test and the p values were computed with De Finetti program [17]. All obese cases are the pooled sample of obese children and severely obese adults.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="3"><bold>Genotype Frequencies</bold></td><td align="center" colspan="2"><bold>Allele Frequencies</bold></td><td align="center"><bold>OR [95%CI] (p value)</bold></td></tr><tr><td colspan="6"><hr></hr></td><td></td></tr><tr><td align="center"><bold>-1839 A&#x0003e;T rs13850</bold></td><td align="center">AA</td><td align="center">AT</td><td align="center">TT</td><td align="center">A</td><td align="center">T</td><td></td></tr></thead><tbody><tr><td align="left"><bold>Obese Children</bold></td><td align="center">384</td><td align="center">128</td><td align="center">21</td><td align="center">0.84</td><td align="center">0.16</td><td align="center">1.10 [0.90&#x02013;1.34] (0.335)</td></tr><tr><td align="left"><bold>Severely obese adults</bold></td><td align="center">475</td><td align="center">164</td><td align="center">20</td><td align="center">0.85</td><td align="center">0.15</td><td align="center">1.06 [0.88&#x02013;1.28] (0.515)</td></tr><tr><td align="left"><bold>All obese</bold></td><td align="center">859</td><td align="center">292</td><td align="center">41</td><td align="center">0.84</td><td align="center">0.16</td><td align="center">1.08 [0.92&#x02013;1.26] (0.327)</td></tr><tr><td align="left"><bold>Type 2 Diabetes</bold></td><td align="center">777</td><td align="center">306</td><td align="center">20</td><td align="center">0.84</td><td align="center">0.16</td><td align="center">1.08 [0.92&#x02013;1.26] (0.339)</td></tr><tr><td align="left"><bold>Controls</bold></td><td align="center">950</td><td align="center">335</td><td align="center">25</td><td align="center">0.85</td><td align="center">0.15</td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center"><bold>-1,701 A&#x0003e;G rs11635997</bold></td><td align="center">AA</td><td align="center">AG</td><td align="center">GG</td><td align="center">A</td><td align="center">G</td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><bold>Obese Children</bold></td><td align="center">191</td><td align="center">267</td><td align="center">90</td><td align="center">0.59</td><td align="center">0.41</td><td align="center">1.14 [0.98&#x02013;1.31] (0.078)</td></tr><tr><td align="left"><bold>Severely obese adults</bold></td><td align="center">266</td><td align="center">322</td><td align="center">101</td><td align="center">0.62</td><td align="center">0.38</td><td align="center">1.01 [0.88&#x02013;1.16] (0.837)</td></tr><tr><td align="left"><bold>All obese</bold></td><td align="center">457</td><td align="center">589</td><td align="center">191</td><td align="center">0.61</td><td align="center">0.39</td><td align="center">1.07 [0.95&#x02013;1.20] (0.255)</td></tr><tr><td align="left"><bold>Type 2 Diabetes</bold></td><td align="center">554</td><td align="center">722</td><td align="center">208</td><td align="center">0.62</td><td align="center">0.38</td><td align="center">1.03 [0.92&#x02013;1.15] (0.619)</td></tr><tr><td align="left"><bold>Controls</bold></td><td align="center">496</td><td align="center">618</td><td align="center">178</td><td align="center">0.62</td><td align="center">0.38</td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center"><bold>-706 C&#x0003e;G rs12595007</bold></td><td align="center">CC</td><td align="center">CG</td><td align="center">GG</td><td align="center">C</td><td align="center">G</td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><bold>Obese Children</bold></td><td align="center">384</td><td align="center">111</td><td align="center">10</td><td align="center">0.87</td><td align="center">0.13</td><td align="center">0.83 [0.67&#x02013;1.10] (0.081)</td></tr><tr><td align="left"><bold>Severely obese adults</bold></td><td align="center">439</td><td align="center">170</td><td align="center">10</td><td align="center">0.85</td><td align="center">0.15</td><td align="center">1.01 [0.84&#x02013;1.21] (0.930)</td></tr><tr><td align="left"><bold>All obese</bold></td><td align="center">823</td><td align="center">281</td><td align="center">20</td><td align="center">0.86</td><td align="center">0.14</td><td align="center">0.92 [0.79&#x02013;1.26] (0.343)</td></tr><tr><td align="left"><bold>Type 2 Diabetes</bold></td><td align="center">976</td><td align="center">352</td><td align="center">21</td><td align="center">0.85</td><td align="center">0.15</td><td align="center">0.95 [0.82&#x02013;1.10] (0.511)</td></tr><tr><td align="left"><bold>Controls</bold></td><td align="center">970</td><td align="center">357</td><td align="center">28</td><td align="center">0.85</td><td align="center">0.15</td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="center"><bold>-304 A&#x0003e;G</bold></td><td align="center">AA</td><td align="center">AG</td><td align="center">GG</td><td align="center">A</td><td align="center">G</td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><bold>Obese Children</bold></td><td align="center">445</td><td align="center">59</td><td align="center">5</td><td align="center">0.93</td><td align="center">0.07</td><td align="center">1.13 [0.84&#x02013;1.51] (0.402)</td></tr><tr><td align="left"><bold>Severely obese adults</bold></td><td align="center">587</td><td align="center">91</td><td align="center">2</td><td align="center">0.93</td><td align="center">0.07</td><td align="center">1.17 [0.90&#x02013;1.52] (0.240)</td></tr><tr><td align="left"><bold>All obese</bold></td><td align="center">1032</td><td align="center">150</td><td align="center">7</td><td align="center">0.93</td><td align="center">0.07</td><td align="center">1.15 [0.92&#x02013;1.44] (0.210)</td></tr><tr><td align="left"><bold>Type 2 Diabetes</bold></td><td align="center">1187</td><td align="center">145</td><td align="center">3</td><td align="center">0.94</td><td align="center">0.06</td><td align="center">0.93 [0.74&#x02013;1.17] (0.555)</td></tr><tr><td align="left"><bold>Controls</bold></td><td align="center">1194</td><td align="center">151</td><td align="center">6</td><td align="center">0.94</td><td align="center">0.06</td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><bold>IVS3 -13,276 T&#x0003e;C rs1406387</bold></td><td align="center">TT</td><td align="center">TC</td><td align="center">CC</td><td align="center">T</td><td align="center">C</td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><bold>Obese Children</bold></td><td align="center">218</td><td align="center">239</td><td align="center">93</td><td align="center">0.61</td><td align="center">0.39</td><td align="center">1.00 [0.86&#x02013;1.15] (0.996)</td></tr><tr><td align="left"><bold>Severely obese adults</bold></td><td align="center">243</td><td align="center">340</td><td align="center">102</td><td align="center">0.60</td><td align="center">0.40</td><td align="center">1.05 [0.91&#x02013;1.19] (0.510)</td></tr><tr><td align="left"><bold>All obese</bold></td><td align="center">461</td><td align="center">579</td><td align="center">195</td><td align="center">0.61</td><td align="center">0.39</td><td align="center">1.02 [0.92&#x02013;1.14] (0.664)</td></tr><tr><td align="left"><bold>Type 2 Diabetes</bold></td><td align="center">552</td><td align="center">729</td><td align="center">251</td><td align="center">0.60</td><td align="center">0.40</td><td align="center">1.06 [0.96&#x02013;1.18] (0.234)</td></tr><tr><td align="left"><bold>Controls</bold></td><td align="center">499</td><td align="center">666</td><td align="center">191</td><td align="center">0.61</td><td align="center">0.39</td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><bold>IVS3-9,221 A&#x0003e;G rs8037112</bold></td><td align="center">AA</td><td align="center">AG</td><td align="center">GG</td><td align="center">A</td><td align="center">G</td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><bold>Obese Children</bold></td><td align="center">219</td><td align="center">233</td><td align="center">91</td><td align="center">0.62</td><td align="center">0.38</td><td align="center">0.96 [0.83&#x02013;1.11] (0.606)</td></tr><tr><td align="left"><bold>Severely obese adults</bold></td><td align="center">260</td><td align="center">322</td><td align="center">95</td><td align="center">0.62</td><td align="center">0.38</td><td align="center">0.95 [0.82&#x02013;1.08] (0.422)</td></tr><tr><td align="left"><bold>All obese</bold></td><td align="center">479</td><td align="center">555</td><td align="center">186</td><td align="center">0.62</td><td align="center">0.38</td><td align="center">0.97 [0.85&#x02013;1.07] (0.408)</td></tr><tr><td align="left"><bold>Type 2 Diabetes</bold></td><td align="center">525</td><td align="center">669</td><td align="center">209</td><td align="center">0.61</td><td align="center">0.39</td><td align="center">0.98 [0.88&#x02013;1.10] (0.774)</td></tr><tr><td align="left"><bold>Controls</bold></td><td align="center">481</td><td align="center">666</td><td align="center">190</td><td align="center">0.61</td><td align="center">0.39</td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><bold>IVS3 -3,045 A&#x0003e;C rs7170561</bold></td><td align="center">AA</td><td align="center">AC</td><td align="center">CC</td><td align="center">A</td><td align="center">C</td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><bold>Obese Children</bold></td><td align="center">248</td><td align="center">211</td><td align="center">66</td><td align="center">0.67</td><td align="center">0.33</td><td align="center">1.04 [0.89&#x02013;1.21] (0.621)</td></tr><tr><td align="left"><bold>Severely obese adults</bold></td><td align="center">318</td><td align="center">282</td><td align="center">79</td><td align="center">0.68</td><td align="center">0.32</td><td align="center">1.03 [0.89&#x02013;1.18] (0.541)</td></tr><tr><td align="left"><bold>All obese</bold></td><td align="center">566</td><td align="center">493</td><td align="center">145</td><td align="center">0.67</td><td align="center">0.33</td><td align="center">1.03 [0.92&#x02013;1.16] (0.598)</td></tr><tr><td align="left"><bold>Type 2 Diabetes</bold></td><td align="center">627</td><td align="center">603</td><td align="center">155</td><td align="center">0.67</td><td align="center">0.33</td><td align="center">1.05 [0.94&#x02013;1.18] (0.372)</td></tr><tr><td align="left"><bold>Controls</bold></td><td align="center">611</td><td align="center">586</td><td align="center">129</td><td align="center">0.68</td><td align="center">0.32</td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><bold>IVS3-2,058 A&#x0003e;Grs28688414</bold></td><td align="center">AA</td><td align="center">AG</td><td align="center">GG</td><td align="center">A</td><td align="center">G</td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><bold>Obese Children</bold></td><td align="center">307</td><td align="center">184</td><td align="center">33</td><td align="center">0.76</td><td align="center">0.24</td><td align="center">1.00 [0.85&#x02013;1.19] (0.959)</td></tr><tr><td align="left"><bold>Severely obese adults</bold></td><td align="center">394</td><td align="center">241</td><td align="center">44</td><td align="center">0.76</td><td align="center">0.24</td><td align="center">1.02 [0.88&#x02013;1.19] (0.750)</td></tr><tr><td align="left"><bold>All obese</bold></td><td align="center">701</td><td align="center">425</td><td align="center">77</td><td align="center">0.76</td><td align="center">0.24</td><td align="center">1.01 [0.89&#x02013;1.15] (0.809)</td></tr><tr><td align="left"><bold>Type 2 Diabetes</bold></td><td align="center">803</td><td align="center">480</td><td align="center">94</td><td align="center">0.76</td><td align="center">0.24</td><td align="center">1.03 [0.91&#x02013;1.16] (0.678)</td></tr><tr><td align="left"><bold>Controls</bold></td><td align="center">778</td><td align="center">499</td><td align="center">71</td><td align="center">0.76</td><td align="center">0.24</td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><bold>IVS3 +823 A&#x0003e;T rs12442397</bold></td><td align="center">AA</td><td align="center">AT</td><td align="center">TT</td><td align="center">A</td><td align="center">T</td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><bold>Obese Children</bold></td><td align="center">249</td><td align="center">215</td><td align="center">70</td><td align="center">0.67</td><td align="center">0.33</td><td align="center">1.14 [0.98&#x02013;1.32] (0.094)</td></tr><tr><td align="left"><bold>Severely obese adults</bold></td><td align="center">320</td><td align="center">293</td><td align="center">64</td><td align="center">0.69</td><td align="center">0.31</td><td align="center">1.03 [0.89&#x02013;1.18] (0.670)</td></tr><tr><td align="left"><bold>All obese</bold></td><td align="center">569</td><td align="center">508</td><td align="center">134</td><td align="center">0.68</td><td align="center">0.32</td><td align="center">1.08 [0.96&#x02013;0.1.21] (0.217)</td></tr><tr><td align="left"><bold>Type 2 Diabetes</bold></td><td align="center">720</td><td align="center">619</td><td align="center">166</td><td align="center">0.68</td><td align="center">0.32</td><td align="center">1.05 [0.94&#x02013;1.18] (0.347)</td></tr><tr><td align="left"><bold>Controls</bold></td><td align="center">642</td><td align="center">583</td><td align="center">117</td><td align="center">0.70</td><td align="center">0.30</td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><bold>IVS3 +881 A&#x0003e;C rs12438604</bold></td><td align="center">AA</td><td align="center">AC</td><td align="center">CC</td><td align="center">A</td><td align="center">C</td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><bold>Obese Children</bold></td><td align="center">323</td><td align="center">184</td><td align="center">35</td><td align="center">0.77</td><td align="center">0.23</td><td align="center">1.16 [0.98&#x02013;1.38] (0.073)</td></tr><tr><td align="left"><bold>Severely obese adults</bold></td><td align="center">416</td><td align="center">238</td><td align="center">27</td><td align="center">0.79</td><td align="center">0.21</td><td align="center">1.04 [0.89&#x02013;1.22] (0.630)</td></tr><tr><td align="left"><bold>All obese</bold></td><td align="center">739</td><td align="center">422</td><td align="center">62</td><td align="center">0.78</td><td align="center">0.22</td><td align="center">1.09 [0.96&#x02013;1.25] (0.181)</td></tr><tr><td align="left"><bold>Type 2 Diabetes</bold></td><td align="center">903</td><td align="center">463</td><td align="center">81</td><td align="center">0.78</td><td align="center">0.22</td><td align="center">1.05 [0.92&#x02013;1.19] (0.459)</td></tr><tr><td align="left"><bold>Controls</bold></td><td align="center">842</td><td align="center">450</td><td align="center">55</td><td align="center">0.79</td><td align="center">0.21</td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><bold>IVS4 +2,853 A&#x0003e;T rs11638903</bold></td><td align="center">AA</td><td align="center">AT</td><td align="center">TT</td><td align="center">A</td><td align="center">T</td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><bold>Obese Children</bold></td><td align="center">286</td><td align="center">199</td><td align="center">61</td><td align="center">0.71</td><td align="center">0.29</td><td align="center">0.98 [0.84&#x02013;1.15] (0.822)</td></tr><tr><td align="left"><bold>Severely obese adults</bold></td><td align="center">335</td><td align="center">291</td><td align="center">56</td><td align="center">0.70</td><td align="center">0.30</td><td align="center">0.99 [0.86&#x02013;1.14] (0.885)</td></tr><tr><td align="left"><bold>All obese</bold></td><td align="center">621</td><td align="center">490</td><td align="center">117</td><td align="center">0.71</td><td align="center">0.29</td><td align="center">0.98 [0.87&#x02013;1.11] (0.822)</td></tr><tr><td align="left"><bold>Type 2 Diabetes</bold></td><td align="center">703</td><td align="center">615</td><td align="center">128</td><td align="center">0.70</td><td align="center">0.30</td><td align="center">1.02 [0.91&#x02013;1.14] (0.772)</td></tr><tr><td align="left"><bold>Controls</bold></td><td align="center">657</td><td align="center">588</td><td align="center">109</td><td align="center">0.70</td><td align="center">0.30</td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><bold>IVS4 +1,514 G&#x0003e;C rs12592208</bold></td><td align="center">GG</td><td align="center">GC</td><td align="center">CC</td><td align="center">G</td><td align="center">C</td><td></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><bold>Obese Children</bold></td><td align="center">281</td><td align="center">195</td><td align="center">65</td><td align="center">0.70</td><td align="center">0.30</td><td align="center">0.96 [0.82&#x02013;1.11] (0.591)</td></tr><tr><td align="left"><bold>Severely obese adults</bold></td><td align="center">313</td><td align="center">289</td><td align="center">58</td><td align="center">0.69</td><td align="center">0.31</td><td align="center">0.99 [0.85&#x02013;1.14] (0.873)</td></tr><tr><td align="left"><bold>All obese</bold></td><td align="center">594</td><td align="center">484</td><td align="center">123</td><td align="center">0.70</td><td align="center">0.30</td><td align="center">0.97 [0.86&#x02013;1.10] (0.678)</td></tr><tr><td align="left"><bold>Type 2 Diabetes</bold></td><td align="center">716</td><td align="center">647</td><td align="center">139</td><td align="center">0.69</td><td align="center">0.31</td><td align="center">0.99 [0.89&#x02013;1.11] (0.911)</td></tr><tr><td align="left"><bold>Controls</bold></td><td align="center">616</td><td align="center">579</td><td align="center">116</td><td align="center">0.69</td><td align="center">0.31</td><td></td></tr></tbody></table></table-wrap><p>We then investigated associations between <italic>SGNE1 </italic>SNPs and obesity related quantitative traits in obese subjects. SNP-1,701A&#x0003e;G, located in intron 1 which is part of the 5' region of <italic>SGNE1 </italic>(Figure <xref ref-type="fig" rid="F1">1</xref>), showed several strong and consistent associations with glucose intolerance. In obese children, despite no significant difference for fasting glucose, SNP -1,701A&#x0003e;G associated with an average 0.5 mmol/l increase (p = 0.0002) in glucose levels 30 min after an OGTT (Figure <xref ref-type="fig" rid="F2">2A</xref>) suggesting that -1,701A&#x0003e;G might alter the early insulin response after a glucose load. Indeed, the allele -1,701A carriers showed a 27% decrease in the insulinogenic index, an estimator of insulin secretion capacity (p = 0.0003) (Figure <xref ref-type="fig" rid="F3">3</xref>). Differences in glucose levels according to -1,701A&#x0003e;G genotypes were still significant after 120 min (p = 0.005). Thus, -1,701A&#x0003e;G associated with a 6% increase in the area under the curve (AUC) for glucose after OGTT (Figure <xref ref-type="fig" rid="F3">3</xref>; p = 0.0001). On the other hand, excepting for a borderline association with fasting insulin levels (p = 0.034), no significant differences were observed according to the -1,701A&#x0003e;G genotype for insulin levels during the OGTT (Figure <xref ref-type="fig" rid="F2">2B</xref>). Consequently, SNP -1,701A&#x0003e;G did not associate with AUC for insulin (p = 0.141) (Figure <xref ref-type="fig" rid="F3">3</xref>). However, the -1,701A allele associated with higher circulating fasting levels of pro-insulin in obese children (p = 0.037, data not shown).</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Plasma glucose (A and B) and plasma insulin (C and D) after OGTTs in obese children (A and C) and obese adults (B and D) according to SNP -1,701A&#x0003e;G (rs11635997) genotypes</bold>. Glucose and insulin levels during OGTT were compared using a general linear model ANOVA for repeated measures, adjusted for age, sex, and BMI. P values are for the dominant model (AA <italic>vs</italic>. AG+GG).</p></caption><graphic xlink:href="1471-2350-8-44-2"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>SNP -1,701A&#x0003e;G associations with insulin and glucose related traits in obese children and obese adults</bold>. Quantitative traits were compared using a General Linear Model ANOVA adjusted for age, sex, and BMI for a dominant model (AA <italic>vs</italic>. AG+GG).*: association is significant after Bonferroni correction (new threshold after correction = 0.0005, see statistical methods for more details).</p></caption><graphic xlink:href="1471-2350-8-44-3"/></fig><p>In obese NGT adults, SNP -1,701A&#x0003e;G was also associated with glucose levels but only after 60 min (p = 0.038) and tended to be associated with higher levels at 90 min (p = 0.06) and 120 min (p = 0.085) (Figure <xref ref-type="fig" rid="F2">2C</xref>). Accordingly, we only observed a trend for an association between -1,701A&#x0003e;G and the AUC for glucose (p = 0.06) in obese adults (Figure <xref ref-type="fig" rid="F3">3</xref>). In addition to association with higher fasting insulin levels (p = 0.028), which was also seen in children, SNP -1,701A&#x0003e;G was associated with higher insulin levels after 60 min (p = 0.013), 90 min (p = 0.012) and 120 min (p = 0.001) (Figure <xref ref-type="fig" rid="F2">2D</xref>). Thus, SNP -1,701A&#x0003e;G associated with a higher AUC for insulin (p = 0.003) (Figure <xref ref-type="fig" rid="F3">3</xref>). SNP -1071A&#x0003e;G also associated with a higher insulin resistance index HOMA-IR in obese children (p = 0.005) and adults (p = 0.009) (Figure <xref ref-type="fig" rid="F3">3</xref>). The associations with AUC glucose and insulinogenic index continue reaching significance after Bonferroni correction in obese children only (for more details, see methods/statistical analyses). No haplotype combination showed stronger or independent association from -1,701A&#x0003e;G with glucose levels, insulinogenic index and HOMA-IR in obese children and obese adults (data not shown).</p><p>We then investigated the role of SNP -1,701A&#x0003e;G in the risk of T2D. We genotyped <italic>SGNE1 </italic>SNPs, including -1,701A&#x0003e;G in an independent population of 1,535 type 2 diabetics. <italic>SGNE1 </italic>SNPs or halpotypes (data not shown) did not associate with T2D (Table <xref ref-type="table" rid="T2">2</xref>) in the whole population or in groups stratified for obesity or age of T2D onset before 45 y (data not shown). Logistic regression using age and sex as covariates did not show any significant association between T2D and SNP -1,701A&#x0003e;G either. Interestingly, SNP -1,701A&#x0003e;G was associated with a higher BMI in type 2 diabetic patients (mean AA = 33.6 &#x000b1; 0.4 kg/m<sup>2 </sup><italic>vs </italic>AG/GG = 32.5 &#x000b1; 0.3 kg/m<sup>2</sup>; p = 0.022, data not shown) but not HbA1C levels (mean AA = 8.26 &#x000b1; 0.1 <italic>vs</italic>. AG/GG 8.42 &#x000b1; 0.1; p = 0.29, data not shown).</p><p>We then aimed to assess if the SNP -1,701A&#x0003e;G modulates traits related to obesity and glucose intolerance in a population-based cohort. Thus, SNP-1,701A&#x0003e;G was also genotyped in 4,922 participants from the D.E.S.I.R prospective study. Cross sectional analyses at baseline did not show an association of SNP -1,701A&#x0003e;G with fasting glucose, fasting insulin, HbA1c levels, HOMA-IR or BMI (data not shown). Only fasting glucose and fasting insulin levels were available for the cohort participants. After 9 years follow-up, allele -1,701G carriers tend to be at lower risk of incidence of overweight (HR = 0.86; p = 0.07), obesity (HR = 0.84; p = 0.10) and T2D (HR = 0.75; p = 0.06) (Figure <xref ref-type="fig" rid="F4">4</xref>).</p><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>Hyperglycemia incidence, by age at baseline, in the DESIR population according to SNP -1,701A&#x0003e;G genotype (dominant model)</bold>. The genotype is considered a risk factor present since birth. The time scale is represented by age (continuous scale). The proportions with overweight (A), obesity (B), hyperglycemia (C) and T2D (D) were calculated within each genotype to assess the impact of SNP-1,701A&#x0003e;G on incidence of all phenotypes studied. Hazard ratios and p values indicated were obtained from Cox proportional hazard survival analyses with age, sex (overweight and obesity) and BMI (hyperglycaemia and T2D) as covariates among AA and AG+GG carriers during the 9 years of follow-up.</p></caption><graphic xlink:href="1471-2350-8-44-4"/></fig></sec><sec><title>Discussion</title><p>Here we describe the genetic study of the pituitary peptide 7B2 encoding gene <italic>SGNE1</italic>, candidate gene for obesity and related metabolic traits. Our study does not provide evidence of association between <italic>SGNE1 </italic>genetic variation and severe forms of obesity in large populations of French Caucasians, including children and adults. However, one SNP, the -1,701A&#x0003e;G, located in the 5' region of <italic>SGNE1</italic>, associate with impaired glucose tolerance in the context of severe obesity but does not increase the risk for T2D. A limitation of our study design is that SNP tagging was based on data from HapMap phase I. According to HapMap phase II data [<xref ref-type="bibr" rid="B20">20</xref>] genotypes from 18 additional TagSNPs would be necessary for an extensive genetic coverage and comprehensive association analyses of <italic>SGNE1 </italic>with metabolic diseases.</p><p>Our results support that SNP -1,071A&#x0003e;G, although not associated with obesity, may contribute to higher glucose levels after OGTT. Similar findings were previously reported for <italic>USF1 </italic>(<italic>Upstream Stimulatory Factor 1</italic>), where SNPs were associated with higher glucose after OGTT, although allelic frequencies were similar between T2D cases and controls [<xref ref-type="bibr" rid="B21">21</xref>]. SNP -1,701A&#x0003e;G also associated with higher HOMA-IR and lower insulinogenic index in obese children. As far as adults are concerned, -1,701A allele carriers compensate the decreased insulin secretion capacity over time but their insulin resistance remained impaired. A high proportion (~75%) of our obese adults self-reported overweight since childhood which may explain a shared genetic background of both populations as previously reported [<xref ref-type="bibr" rid="B22">22</xref>]. However, their metabolic profile is fairly diverse: 94% of obese children are glucose tolerant after OGTT, against only 52% of the severely obese adults. These data may elucidate the observed heterogeneity between quantitative traits associations in children and adults. We also believe that obesity related quantitative traits results should be interpreted with caution in adults as these analyses are more meaningful in obese children [<xref ref-type="bibr" rid="B23">23</xref>].</p><p>SNP-1,701A&#x0003e;G is located in intron 1 and is part of the 5' region of <italic>SGNE1</italic>. It has been shown that intron 1 sequences are essential for transcriptional activity of <italic>SGNE1 </italic>in human cell lines [<xref ref-type="bibr" rid="B24">24</xref>]. A recent study has also shown that intron 1 of <italic>SGNE1 </italic>is hypermethylated and epigenetically silenced in medulloblastomas [<xref ref-type="bibr" rid="B25">25</xref>]. This data supports an important role of intron 1 of <italic>SGNE1 </italic>and a potential functional role of SNP -1,701A&#x0003e;G in the regulation of <italic>SGNE1</italic>. According to <italic>in silico </italic>analyses [<xref ref-type="bibr" rid="B26">26</xref>], SNP -1,701A creates a theoretical binding site for <italic>TCF/LEF1 </italic>(Transcription Factor T-Cell specific/Lymphoid Enhancer binding Factor1). To our knowledge, <italic>TCF/LEF1 </italic>role in metabolism has not been described. We note that <italic>TCF/LEF1 </italic>belongs to the Wnt signaling pathway that includes <italic>TCL7L2</italic>, which harbours highly associated SNPs with T2D [<xref ref-type="bibr" rid="B27">27</xref>]. Further molecular studies are required to elucidate how SNP -1,701A&#x0003e;G would affect the expression and function of <italic>SGNE1 </italic>and ultimately impaired metabolism. An increase of 7B2 has been reported in pancreas from <italic>ob/ob </italic>mice compared to wild type mice [<xref ref-type="bibr" rid="B28">28</xref>] suggesting that 7B2 may increase in insulin resistance state. Thus, as 7B2 is immunologically detected in human plasma [<xref ref-type="bibr" rid="B29">29</xref>], analyses of association between SNP -1,701A&#x0003e;G and 7B2 plasma levels in our populations would provide a value indication about how this genetic variant might impact <italic>SGNE1 </italic>functionality and consequently, glucose tolerance and insulin resistance.</p><p>As a protein helper and activator of PC2, 7B2 is involved in the maturation of a large spectrum of molecules playing central roles in weight and glucose homeostasis [<xref ref-type="bibr" rid="B5">5</xref>]. 7B2 and PC2 are highly expressed in secretory granules of pancreatic islets and are involved in processing of insulin in &#x003b2;-cells and glucagon in &#x003b1;-cell [<xref ref-type="bibr" rid="B5">5</xref>]. High levels of circulating pro-insulin and pro-glucagon have been described in 7B2 knock-out mice confirming the role of 7B2 in insulin and glucagon maturation [<xref ref-type="bibr" rid="B30">30</xref>]. If associations and functionality of SNP -1,701A&#x0003e;G are confirmed, we hypothesize that higher glucose levels and lower insulin secretion observed in -1,701A allele carriers could be direct, as a consequence of impairment of the processing and/or secretion of insulin. The observed SNP -1,701A&#x0003e;G associations with higher pro-insulin levels and lower insulinogenic index in obese children support this hypothesis. Insulin secretion could also be indirectly affected through alteration of glucagon processing that requires both PC2 and 7B2. Thus, impairment of glucagon processing may affect insulin secretion and results in increase glucose levels. This hypothesis is supported by a recent study where low circulating glucagon levels accompanied with low 7B2 mRNA and protein levels (but not PC2 levels) were reported in pancreas of a mouse strain highly predisposed to age associated glucose intolerance [<xref ref-type="bibr" rid="B31">31</xref>]. Because of the pleitropic function of 7B2, several mechanisms would result from the alteration of its regulation. Other metabolic pathways could also be affected, such as the processing of cholecystokinin (CCK) [<xref ref-type="bibr" rid="B32">32</xref>], a gastrointestine peptide that stimulates insulin secretion from &#x003b2;-cells in healthy subjects [<xref ref-type="bibr" rid="B33">33</xref>] and the maturation of anorexigenic neuropeptides CART [<xref ref-type="bibr" rid="B11">11</xref>] and POMC [<xref ref-type="bibr" rid="B10">10</xref>] involved in the regulation of energy balance.</p></sec><sec><title>Conclusion</title><p>In summary, we report genetic evidence for the role of <italic>SGNE1 </italic>genetic variation in glucose intolerance and insulin resistance in the background of young onset obesity. Further analyses are required to replicate our findings and to understand the molecular bases of <italic>SGNE1 </italic>role in the genetic susceptibility to the risk of glucose intolerance in response to glucose load.</p></sec><sec><title>Abbreviations</title><p>AUC Area under curve</p><p>BMI Body mass index</p><p>CART Cocaine amphetamine regulated transcript</p><p>CCK Cholecystokinin</p><p>HOMA-IR Homeostasis model assessment &#x02013; insulin resistance</p><p>IFG Intolerant fasting glucose</p><p>NGT Normal glucose tolerant</p><p>OGTT Oral glucose tolerance test</p><p>PC2 Proprotein convertase 2</p><p>PCR Pomymerase chain reaction</p><p>POMC Pro-opiomelanocortin</p><p>SGNE1 Secretory granule neuroendocrine protein 1</p><p>SNP Single nucleotide polymorphism</p><p>T2D Type 2 diabetes</p><p>TCF/LEF1 Transcription factor t-cell specific/lymphoid enhancer binding factor 1</p><p>TCF7L2 Transcription factor t-cell specific 7-like 2</p><p>USF1 Upstream Stimulatory Factor 1</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>NBN and VV performed the genotyping. NBN, CL, JV, CP and DM performed the statistical analyses. DNA was provided by GC, BH, JT, MM and BB. NBN drafted the manuscript under PF and DM supervision. DM and PF supervised the study. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/8/44/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This work was partly supported by the association "200 Familles pour Vaincre le Diab&#x000e8;te et l'Ob&#x000e9;sit&#x000e9;", the Association Fran&#x000e7;aise des Diab&#x000e9;tiques (AFD), an AFERO/Roche research prize. The D.E.S.I.R study was supported by co-operative contracts between INSERM, CNAMTS and Novartis Pharma, INSERM (R&#x000e9;seaux en Sant&#x000e9; Publique, Interactions entre les d&#x000e9;terminants de la sant&#x000e9;), the Association Diab&#x000e8;te Risque Vasculaire, the F&#x000e9;d&#x000e9;ration Fran&#x000e7;aise de Cardiologie, La Fondation de France, ALFEDIAM, ONIVINS; Ardix Medical, Bayer Diagnostics, Becton Dickinson, Cardionics, Lilly, Merck Sant&#x000e9;, Novo Nordisk, Pierre Fabre, Roche, Sanofi, Topcon. We thank Olfert Landt at Tib-Molbiol, Germany, Cecile Giles and Chantal Samson for technical assistance and Christophe Wachter and Stefan Gaget for bioinformatics assistance. We are indebted to all subjects who volunteered in this study.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mokdad</surname><given-names>AH</given-names></name><name><surname>Ford</surname><given-names>ES</given-names></name><name><surname>Bowman</surname><given-names>BA</given-names></name><name><surname>Dietz</surname><given-names>WH</given-names></name><name><surname>Vinicor</surname><given-names>F</given-names></name><name><surname>Bales</surname><given-names>VS</given-names></name><name><surname>Marks</surname><given-names>JS</given-names></name></person-group><article-title>Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001</article-title><source>Jama</source><year>2003</year><volume>289</volume><fpage>76</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">12503980</pub-id><pub-id pub-id-type="doi">10.1001/jama.289.1.76</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>R</given-names></name><name><surname>Dziura</surname><given-names>J</given-names></name><name><surname>Burgert</surname><given-names>TS</given-names></name><name><surname>Tamborlane</surname><given-names>WV</given-names></name><name><surname>Taksali</surname><given-names>SE</given-names></name><name><surname>Yeckel</surname><given-names>CW</given-names></name><name><surname>Allen</surname><given-names>K</given-names></name><name><surname>Lopes</surname><given-names>M</given-names></name><name><surname>Savoye</surname><given-names>M</given-names></name><name><surname>Morrison</surname><given-names>J</given-names></name><name><surname>Sherwin</surname><given-names>RS</given-names></name><name><surname>Caprio</surname><given-names>S</given-names></name></person-group><article-title>Obesity and the metabolic syndrome in children and adolescents</article-title><source>N Engl J Med</source><year>2004</year><volume>350</volume><fpage>2362</fpage><lpage>2374</lpage><pub-id pub-id-type="pmid">15175438</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa031049</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>CG</given-names></name><name><surname>Walley</surname><given-names>AJ</given-names></name><name><surname>Froguel</surname><given-names>P</given-names></name></person-group><article-title>The genetics of human obesity</article-title><source>Nat Rev Genet</source><year>2005</year><volume>6</volume><fpage>221</fpage><lpage>234</lpage><pub-id pub-id-type="pmid">15703762</pub-id><pub-id pub-id-type="doi">10.1038/nrg1556</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meyre</surname><given-names>D</given-names></name><name><surname>Lecoeur</surname><given-names>C</given-names></name><name><surname>Delplanque</surname><given-names>J</given-names></name><name><surname>Francke</surname><given-names>S</given-names></name><name><surname>Vatin</surname><given-names>V</given-names></name><name><surname>Durand</surname><given-names>E</given-names></name><name><surname>Weill</surname><given-names>J</given-names></name><name><surname>Dina</surname><given-names>C</given-names></name><name><surname>Froguel</surname><given-names>P</given-names></name></person-group><article-title>A genome-wide scan for childhood obesity-associated traits in French families shows significant linkage on chromosome 6q22.31-q23.2</article-title><source>Diabetes</source><year>2004</year><volume>53</volume><fpage>803</fpage><lpage>811</lpage><pub-id pub-id-type="pmid">14988267</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.53.3.803</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mbikay</surname><given-names>M</given-names></name><name><surname>Seidah</surname><given-names>NG</given-names></name><name><surname>Chretien</surname><given-names>M</given-names></name></person-group><article-title>Neuroendocrine secretory protein 7B2: structure, expression and functions</article-title><source>Biochem J</source><year>2001</year><volume>357</volume><fpage>329</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">11439082</pub-id><pub-id pub-id-type="doi">10.1042/0264-6021:3570329</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seidel</surname><given-names>B</given-names></name><name><surname>Dong</surname><given-names>W</given-names></name><name><surname>Savaria</surname><given-names>D</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Pintar</surname><given-names>JE</given-names></name><name><surname>Day</surname><given-names>R</given-names></name></person-group><article-title>Neuroendocrine protein 7B2 is essential for proteolytic conversion and activation of proprotein convertase 2 in vivo</article-title><source>DNA Cell Biol</source><year>1998</year><volume>17</volume><fpage>1017</fpage><lpage>1029</lpage><pub-id pub-id-type="pmid">9881669</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Braks</surname><given-names>JA</given-names></name><name><surname>Martens</surname><given-names>GJ</given-names></name></person-group><article-title>7B2 is a neuroendocrine chaperone that transiently interacts with prohormone convertase PC2 in the secretory pathway</article-title><source>Cell</source><year>1994</year><volume>78</volume><fpage>263</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">7913882</pub-id><pub-id pub-id-type="doi">10.1016/0092-8674(94)90296-8</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>M</given-names></name><name><surname>Carroll</surname><given-names>R</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name><name><surname>Swift</surname><given-names>HH</given-names></name><name><surname>Ravazzola</surname><given-names>M</given-names></name><name><surname>Orci</surname><given-names>L</given-names></name><name><surname>Steiner</surname><given-names>DF</given-names></name></person-group><article-title>Incomplete processing of proinsulin to insulin accompanied by elevation of Des-31,32 proinsulin intermediates in islets of mice lacking active PC2</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><fpage>3431</fpage><lpage>3437</lpage><pub-id pub-id-type="pmid">9452465</pub-id><pub-id pub-id-type="doi">10.1074/jbc.273.6.3431</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>A</given-names></name><name><surname>Webb</surname><given-names>G</given-names></name><name><surname>Carroll</surname><given-names>R</given-names></name><name><surname>Ravazzola</surname><given-names>M</given-names></name><name><surname>Orci</surname><given-names>L</given-names></name><name><surname>Steiner</surname><given-names>DF</given-names></name></person-group><article-title>Severe defect in proglucagon processing in islet A-cells of prohormone convertase 2 null mice</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>27197</fpage><lpage>27202</lpage><pub-id pub-id-type="pmid">11356850</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M103362200</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laurent</surname><given-names>V</given-names></name><name><surname>Jaubert-Miazza</surname><given-names>L</given-names></name><name><surname>Desjardins</surname><given-names>R</given-names></name><name><surname>Day</surname><given-names>R</given-names></name><name><surname>Lindberg</surname><given-names>I</given-names></name></person-group><article-title>Biosynthesis of proopiomelanocortin-derived peptides in prohormone convertase 2 and 7B2 null mice</article-title><source>Endocrinology</source><year>2004</year><volume>145</volume><fpage>519</fpage><lpage>528</lpage><pub-id pub-id-type="pmid">14576186</pub-id><pub-id pub-id-type="doi">10.1210/en.2003-0829</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dey</surname><given-names>A</given-names></name><name><surname>Xhu</surname><given-names>X</given-names></name><name><surname>Carroll</surname><given-names>R</given-names></name><name><surname>Turck</surname><given-names>CW</given-names></name><name><surname>Stein</surname><given-names>J</given-names></name><name><surname>Steiner</surname><given-names>DF</given-names></name></person-group><article-title>Biological processing of the cocaine and amphetamine-regulated transcript precursors by prohormone convertases, PC2 and PC1/3</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>15007</fpage><lpage>15014</lpage><pub-id pub-id-type="pmid">12584191</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M212128200</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bergeron</surname><given-names>F</given-names></name><name><surname>Sirois</surname><given-names>F</given-names></name><name><surname>Mbikay</surname><given-names>M</given-names></name></person-group><article-title>ACTH secretion by mouse corticotroph AtT20 cells is negatively modulated by the intracellular level of 7B2</article-title><source>FEBS Lett</source><year>2002</year><volume>512</volume><fpage>259</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">11852092</pub-id><pub-id pub-id-type="doi">10.1016/S0014-5793(02)02277-9</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sarac</surname><given-names>MS</given-names></name><name><surname>Zieske</surname><given-names>AW</given-names></name><name><surname>Lindberg</surname><given-names>I</given-names></name></person-group><article-title>The lethal form of Cushing's in 7B2 null mice is caused by multiple metabolic and hormonal abnormalities</article-title><source>Endocrinology</source><year>2002</year><volume>143</volume><fpage>2324</fpage><lpage>2332</lpage><pub-id pub-id-type="pmid">12021197</pub-id><pub-id pub-id-type="doi">10.1210/en.143.6.2324</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peinado</surname><given-names>JR</given-names></name><name><surname>Laurent</surname><given-names>V</given-names></name><name><surname>Lee</surname><given-names>SN</given-names></name><name><surname>Peng</surname><given-names>BW</given-names></name><name><surname>Pintar</surname><given-names>JE</given-names></name><name><surname>Steiner</surname><given-names>DF</given-names></name><name><surname>Lindberg</surname><given-names>I</given-names></name></person-group><article-title>Strain-dependent influences on the hypothalamo-pituitary-adrenal axis profoundly affect the 7B2 and PC2 null phenotypes</article-title><source>Endocrinology</source><year>2005</year><volume>146</volume><fpage>3438</fpage><lpage>3444</lpage><pub-id pub-id-type="pmid">15878971</pub-id><pub-id pub-id-type="doi">10.1210/en.2004-1289</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Laurent</surname><given-names>V</given-names></name><name><surname>Kimble</surname><given-names>A</given-names></name><name><surname>Peng</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>P</given-names></name><name><surname>Pintar</surname><given-names>JE</given-names></name><name><surname>Steiner</surname><given-names>DF</given-names></name><name><surname>Lindberg</surname><given-names>I</given-names></name></person-group><article-title>Mortality in 7B2 null mice can be rescued by adrenalectomy: involvement of dopamine in ACTH hypersecretion</article-title><source>Proc Natl Acad Sci U S A</source><year>2002</year><volume>99</volume><fpage>3087</fpage><lpage>3092</lpage><pub-id pub-id-type="pmid">11854475</pub-id><pub-id pub-id-type="doi">10.1073/pnas.261715099</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rolland-Cachera</surname><given-names>MF</given-names></name><name><surname>Cole</surname><given-names>TJ</given-names></name><name><surname>Sempe</surname><given-names>M</given-names></name><name><surname>Tichet</surname><given-names>J</given-names></name><name><surname>Rossignol</surname><given-names>C</given-names></name><name><surname>Charraud</surname><given-names>A</given-names></name></person-group><article-title>Body Mass Index variations: centiles from birth to 87 years</article-title><source>Eur J Clin Nutr</source><year>1991</year><volume>45</volume><fpage>13</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">1855495</pub-id></citation></ref><ref id="B17"><citation citation-type="other"><article-title>Tests for deviation from Hardy-Weinberg equilibrium and tests for association</article-title><ext-link ext-link-type="uri" xlink:href="http://ihg.gsf.de/cgi-bin/hw/hwa1.pl"/></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tregouet</surname><given-names>DA</given-names></name><name><surname>Escolano</surname><given-names>S</given-names></name><name><surname>Tiret</surname><given-names>L</given-names></name><name><surname>Mallet</surname><given-names>A</given-names></name><name><surname>Golmard</surname><given-names>JL</given-names></name></person-group><article-title>A new algorithm for haplotype-based association analysis: the Stochastic-EM algorithm</article-title><source>Ann Hum Genet</source><year>2004</year><volume>68</volume><fpage>165</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">15008795</pub-id><pub-id pub-id-type="doi">10.1046/j.1529-8817.2003.00085.x</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dudbridge</surname><given-names>F</given-names></name><name><surname>Koeleman</surname><given-names>BP</given-names></name><name><surname>Todd</surname><given-names>JA</given-names></name><name><surname>Clayton</surname><given-names>DG</given-names></name></person-group><article-title>Unbiased application of the transmission/disequilibrium test to multilocus haplotypes</article-title><source>Am J Hum Genet</source><year>2000</year><volume>66</volume><fpage>2009</fpage><lpage>2012</lpage><pub-id pub-id-type="pmid">10775523</pub-id><pub-id pub-id-type="doi">10.1086/302915</pub-id></citation></ref><ref id="B20"><citation citation-type="other"><person-group person-group-type="author"><collab>Hapmap</collab></person-group><article-title>Hapmap web site</article-title><year>2005</year></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Putt</surname><given-names>W</given-names></name><name><surname>Palmen</surname><given-names>J</given-names></name><name><surname>Nicaud</surname><given-names>V</given-names></name><name><surname>Tregouet</surname><given-names>DA</given-names></name><name><surname>Tahri-Daizadeh</surname><given-names>N</given-names></name><name><surname>Flavell</surname><given-names>DM</given-names></name><name><surname>Humphries</surname><given-names>SE</given-names></name><name><surname>Talmud</surname><given-names>PJ</given-names></name></person-group><article-title>Variation in USF1 shows haplotype effects, gene : gene and gene : environment associations with glucose and lipid parameters in the European Atherosclerosis Research Study II</article-title><source>Hum Mol Genet</source><year>2004</year><volume>13</volume><fpage>1587</fpage><lpage>1597</lpage><pub-id pub-id-type="pmid">15175273</pub-id><pub-id pub-id-type="doi">10.1093/hmg/ddh168</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bouatia-Naji</surname><given-names>N</given-names></name><name><surname>Meyre</surname><given-names>D</given-names></name><name><surname>Lobbens</surname><given-names>S</given-names></name><name><surname>Seron</surname><given-names>K</given-names></name><name><surname>Fumeron</surname><given-names>F</given-names></name><name><surname>Balkau</surname><given-names>B</given-names></name><name><surname>Heude</surname><given-names>B</given-names></name><name><surname>Jouret</surname><given-names>B</given-names></name><name><surname>Scherer</surname><given-names>PE</given-names></name><name><surname>Dina</surname><given-names>C</given-names></name><name><surname>Weill</surname><given-names>J</given-names></name><name><surname>Froguel</surname><given-names>P</given-names></name></person-group><article-title>ACDC/adiponectin polymorphisms are associated with severe childhood and adult obesity</article-title><source>Diabetes</source><year>2006</year><volume>55</volume><fpage>545</fpage><lpage>550</lpage><pub-id pub-id-type="pmid">16443793</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.55.02.06.db05-0971</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bougneres</surname><given-names>P</given-names></name></person-group><article-title>Genetics of obesity and type 2 diabetes: tracking pathogenic traits during the predisease period</article-title><source>Diabetes</source><year>2002</year><volume>51 Suppl 3</volume><fpage>S295</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">12475766</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.51.2007.S295</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gherzi</surname><given-names>R</given-names></name><name><surname>Fehmann</surname><given-names>HC</given-names></name><name><surname>Eissele</surname><given-names>R</given-names></name><name><surname>Goke</surname><given-names>B</given-names></name></person-group><article-title>Expression, intracellular localization, and gene transcription regulation of the secretory protein 7B2 in endocrine pancreatic cell lines and human insulinomas</article-title><source>Exp Cell Res</source><year>1994</year><volume>213</volume><fpage>20</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">7517367</pub-id><pub-id pub-id-type="doi">10.1006/excr.1994.1168</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waha</surname><given-names>A</given-names></name><name><surname>Koch</surname><given-names>A</given-names></name><name><surname>Hartmann</surname><given-names>W</given-names></name><name><surname>Milde</surname><given-names>U</given-names></name><name><surname>Felsberg</surname><given-names>J</given-names></name><name><surname>Hubner</surname><given-names>A</given-names></name><name><surname>Mikeska</surname><given-names>T</given-names></name><name><surname>Goodyer</surname><given-names>CG</given-names></name><name><surname>Sorensen</surname><given-names>N</given-names></name><name><surname>Lindberg</surname><given-names>I</given-names></name><name><surname>Wiestler</surname><given-names>OD</given-names></name><name><surname>Pietsch</surname><given-names>T</given-names></name><name><surname>Waha</surname><given-names>A</given-names></name></person-group><article-title>SGNE1/7B2 is epigenetically altered and transcriptionally downregulated in human medulloblastomas</article-title><source>Oncogene</source><year>2007</year><pub-id pub-id-type="pmid">17334394</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cartharius</surname><given-names>K</given-names></name><name><surname>Frech</surname><given-names>K</given-names></name><name><surname>Grote</surname><given-names>K</given-names></name><name><surname>Klocke</surname><given-names>B</given-names></name><name><surname>Haltmeier</surname><given-names>M</given-names></name><name><surname>Klingenhoff</surname><given-names>A</given-names></name><name><surname>Frisch</surname><given-names>M</given-names></name><name><surname>Bayerlein</surname><given-names>M</given-names></name><name><surname>Werner</surname><given-names>T</given-names></name></person-group><article-title>MatInspector and beyond: promoter analysis based on transcription factor binding sites</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><fpage>2933</fpage><lpage>2942</lpage><pub-id pub-id-type="pmid">15860560</pub-id><pub-id pub-id-type="doi">10.1093/bioinformatics/bti473</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cauchi</surname><given-names>S</given-names></name><name><surname>Meyre</surname><given-names>D</given-names></name><name><surname>Dina</surname><given-names>C</given-names></name><name><surname>Choquet</surname><given-names>H</given-names></name><name><surname>Samson</surname><given-names>C</given-names></name><name><surname>Gallina</surname><given-names>S</given-names></name><name><surname>Balkau</surname><given-names>B</given-names></name><name><surname>Charpentier</surname><given-names>G</given-names></name><name><surname>Pattou</surname><given-names>F</given-names></name><name><surname>Stetsyuk</surname><given-names>V</given-names></name><name><surname>Scharfmann</surname><given-names>R</given-names></name><name><surname>Staels</surname><given-names>B</given-names></name><name><surname>Fruhbeck</surname><given-names>G</given-names></name><name><surname>Froguel</surname><given-names>P</given-names></name></person-group><article-title>Transcription factor TCF7L2 genetic study in the French population: expression in human beta-cells and adipose tissue and strong association with type 2 diabetes</article-title><source>Diabetes</source><year>2006</year><volume>55</volume><fpage>2903</fpage><lpage>2908</lpage><pub-id pub-id-type="pmid">17003360</pub-id><pub-id pub-id-type="doi">10.2337/db06-0474</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Ohtake</surname><given-names>R</given-names></name><name><surname>Kobori</surname><given-names>H</given-names></name><name><surname>Hashigami</surname><given-names>Y</given-names></name><name><surname>Shimoda</surname><given-names>SI</given-names></name></person-group><article-title>Pituitary, hypothalamic and pancreatic 7B2 concentrations in rats with streptozotocin-induced diabetes and spontaneously diabetic mice</article-title><source>Pancreas</source><year>1988</year><volume>3</volume><fpage>662</fpage><lpage>667</lpage><pub-id pub-id-type="pmid">3065775</pub-id><pub-id pub-id-type="doi">10.1097/00006676-198812000-00006</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Kobori</surname><given-names>H</given-names></name><name><surname>Ohtake</surname><given-names>R</given-names></name><name><surname>Hashigami</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Shimoda</surname><given-names>SI</given-names></name><name><surname>Bloom</surname><given-names>SR</given-names></name></person-group><article-title>Circulating concentrations of immunoreactive peptide 7B2 in certain pathophysiological conditions, and response to oral glucose load</article-title><source>Clin Chem</source><year>1988</year><volume>34</volume><fpage>410</fpage><lpage>413</lpage><pub-id pub-id-type="pmid">3342519</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Westphal</surname><given-names>CH</given-names></name><name><surname>Muller</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>A</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Bonner-Weir</surname><given-names>S</given-names></name><name><surname>Schambelan</surname><given-names>M</given-names></name><name><surname>Steiner</surname><given-names>DF</given-names></name><name><surname>Lindberg</surname><given-names>I</given-names></name><name><surname>Leder</surname><given-names>P</given-names></name></person-group><article-title>The neuroendocrine protein 7B2 is required for peptide hormone processing in vivo and provides a novel mechanism for pituitary Cushing's disease</article-title><source>Cell</source><year>1999</year><volume>96</volume><fpage>689</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">10089884</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80579-6</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>G</given-names></name><name><surname>Sirois</surname><given-names>F</given-names></name><name><surname>Anini</surname><given-names>Y</given-names></name><name><surname>Kauri</surname><given-names>LM</given-names></name><name><surname>Gyamera-Acheampong</surname><given-names>C</given-names></name><name><surname>Fleck</surname><given-names>E</given-names></name><name><surname>Scott</surname><given-names>FW</given-names></name><name><surname>Chretien</surname><given-names>M</given-names></name><name><surname>Mbikay</surname><given-names>M</given-names></name></person-group><article-title>Differences of pancreatic expression of 7B2 between C57BL/6J and C3H/HeJ mice and genetic polymorphisms at its locus (Sgne1)</article-title><source>Diabetes</source><year>2006</year><volume>55</volume><fpage>452</fpage><lpage>459</lpage><pub-id pub-id-type="pmid">16443780</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.55.02.06.db05-0733</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rehfeld</surname><given-names>JF</given-names></name><name><surname>Lindberg</surname><given-names>I</given-names></name><name><surname>Friis-Hansen</surname><given-names>L</given-names></name></person-group><article-title>Increased synthesis but decreased processing of neuronal proCCK in prohormone convertase 2 and 7B2 knockout animals</article-title><source>J Neurochem</source><year>2002</year><volume>83</volume><fpage>1329</fpage><lpage>1337</lpage><pub-id pub-id-type="pmid">12472887</pub-id><pub-id pub-id-type="doi">10.1046/j.1471-4159.2002.01244.x</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niederau</surname><given-names>C</given-names></name><name><surname>Schwarzendrube</surname><given-names>J</given-names></name><name><surname>Luthen</surname><given-names>R</given-names></name><name><surname>Niederau</surname><given-names>M</given-names></name><name><surname>Strohmeyer</surname><given-names>G</given-names></name><name><surname>Rovati</surname><given-names>L</given-names></name></person-group><article-title>Effects of cholecystokinin receptor blockade on circulating concentrations of glucose, insulin, C-peptide, and pancreatic polypeptide after various meals in healthy human volunteers</article-title><source>Pancreas</source><year>1992</year><volume>7</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">1557335</pub-id></citation></ref></ref-list></back></article> 